Propanc Biopharma, Inc. PPCB
Set alert
At close · Oct 30
After hours · Oct 30, 7:06 PM ET
- YTD
- -98.63%
- 1 year
- -99.41%
- Open
- 1.91
- Prev close
- 2.11
- Mkt cap
- 1.90M
- Vol
- 65.61K
- Avg vol
- 188.07K
- EPS
- -176.20
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.82
- High
- 2.13
- Earnings
- Sep 27, 2023
5D chart
Events in this range
- Oct 26, 2026Split: 1 for 10
Signals (65)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 1:45 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 11:55 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 2 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 28, 9:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 27, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 26, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:20 PM | 5 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 26, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 23, 2:55 PM | 1 week ago |
| SMA: Bullish | Oct 23, 2:55 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:45 PM | 1 week ago |
| SMA: Bearish | Oct 23, 2:45 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:35 PM | 1 week ago |
| SMA: Bullish | Oct 23, 1:35 PM | 1 week ago |
| SMA: Bearish | Oct 23, 11:45 AM | 1 week ago |
| SMA: Bullish | Oct 23, 11:30 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:25 AM | 1 week ago |
| SMA: Bullish | Oct 23, 11:15 AM | 1 week ago |
| SMA: Bearish | Oct 23, 11:05 AM | 1 week ago |
| SMA: Bullish | Oct 23, 11:00 AM | 1 week ago |
| SMA: Bearish | Oct 23, 10:55 AM | 1 week ago |
| SMA: Bullish | Oct 23, 10:20 AM | 1 week ago |
News
1 day ago globenewswire.com
Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients
MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
-
3 days ago benzinga.com
Propanc Biopharma Continues Clinical Development Program For Propanc Proenzyme; Targets February 2027 For Its First Clinical Site Initiation
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
3 days ago globenewswire.com
Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients
"The continued advancement
-
5 days ago benzinga.com
Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59%
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
5 days ago globenewswire.com
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
We envision PRP as a long-term, metronomic therapy that minimizes the threat of recurrence while enabling patients to better respond to standard treatments
1 week ago globenewswire.com
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
"
-
1 week ago benzinga.com
Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
1 week ago globenewswire.com
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
-
2 weeks ago benzinga.com
Propanc Biopharma Announces It Has Identified Pancreatic Proenzyme Formulation As Potential Strategy For Addressing Chemotherapy Resistance In Pancreatic Cancer
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer,
2 weeks ago globenewswire.com
Propanc Biopharma's Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
MELBOURNE, Australia, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
2 weeks ago globenewswire.com
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
MELBOURNE, Australia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
2 weeks ago defenseworld.net
Propanc Biopharma Inc (NASDAQ:PPCB) Sees Significant Increase in Short Interest
Propanc Biopharma Inc (NASDAQ: PPCB - Get Free Report) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 71,162…
3 weeks ago globenewswire.com
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib
MELBOURNE, Australia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
-
3 weeks ago benzinga.com
Propanc Biopharma Registers Resale Of 6,500,000 Shares Of Common Stock
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001517681/000149315226045770/forms-1.htm
1 month ago globenewswire.com
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
"The Company is poised to capitalize on the foundation set
-
1 month ago benzinga.com
Propanc Biopharma Analysis Of PRP Against Clinical Datasets From Erasca Demonstrates PRP Does Not Exhibit RAS
Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
1 month ago globenewswire.com
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca's Phase 1 ERAS-0015…
-
1 month ago benzinga.com
Propanc Biopharma Issues Comparative Analysis Of Lead Candidate PRP Against Clinical Datasets From RAS-Targeted Programs, Including Revolution Medicines’ Daraxonrasib And Erasca’s Pan-RAS Molecular Glue ERAS-0015
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
1 month ago globenewswire.com
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
MELBOURNE, Australia, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
1 month ago globenewswire.com
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) shares moved…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 41.4% to $7.29 during Friday's pre-market session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) stock moved…
2 months ago benzinga.com
Why Elastic Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Elastic NV (ESTC) stock rose 21.8% in pre-market trading after reporting strong Q1 results and raising FY27 guidance. Other top gainers include WHLR, QNRX, AEMD, NA, SOLS, HYNE, GAP, AFRM, and ARKR.…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock…
2 months ago benzinga.com
Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings
U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma…
2 months ago benzinga.com
Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results
Propanc Biopharma Inc. (NASDAQ:PPCB) stock surged on Thursday after compelling preclinical and early translational data for its primary drug candidate, PRP, focused on treating pancreatic ductal…
2 months ago benzinga.com
Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results
Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.
2 months ago benzinga.com
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results
US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings.…
2 months ago globenewswire.com
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
2 months ago globenewswire.com
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
MELBOURNE, Australia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
2 months ago globenewswire.com
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and spread
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global…
-
2 months ago benzinga.com
Propanc Biopharma Announces New Preclinical And Translational Data For Lead Candidate PRP In Pancreatic Ductal Adenocarcinoma
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
2 months ago globenewswire.com
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX)…
2 months ago globenewswire.com
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
MELBOURNE, Australia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
-
3 months ago benzinga.com
Propanc Biopharma Announces Publication Of Evaluation Of Recombinant Trypsinogen And Chymotrypsinogen In Peer-Reviewed Journal Microbial Cell Factories
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
3 months ago globenewswire.com
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
MELBOURNE, Australia, July 21, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's after-market session. The company's market cap stands at $2.0 million. Ironwood Pharmaceuticals…
-
4 months ago benzinga.com
11 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma…
-
4 months ago benzinga.com
10 Health Care Stocks Moving In Monday's Pre-Market Session
10 Health Care Stocks Moving In Monday's Pre-Market Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
4 months ago benzinga.com
Why Friedman Industries Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Friedman Industries Inc (NASDAQ: FRD) rose in pre-market trading after posting strong Q4 earnings. Other gainers include BYAH, VSME, ADTX, EDHL, GMM, HKIT, RKTO, ASYS, and PWRL. Losers include GELS,…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
4 months ago benzinga.com
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings
US stocks rise with Nasdaq up 150 points. Dow up 0.54%, Nasdaq up 0.63%, S&P 500 up 0.26%. Industrials and Enliven Therapeutics lead gains. Dana Inc and Oracle Corp down. Oil up 0.7%, gold down 0.7%.…
4 months ago benzinga.com
Dow Jumps Over 250 Points; US Initial Jobless Claims Rise
US stocks up, Dow gains 250 pts. Dow up 0.58% while NASDAQ up 0.67%. Materials shares jump 1.5%, communication services down 1.3%. Jobless claims up.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session